Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Johnson & Johnson Takes Good Care of Business
- Ockham Research submits: Johnson & Johnson JNJ reported earnings Tuesday morning that beat expectations and reaffirmed JNJ as a safe harbor in this extremely volatile market. We have been fairly bullish on JNJ for some time but, as of September 27th, we have the stock rated “Greatly Undervalued”, our...
- External links 2008-10-15
- NBTY May Keep Investors Healthy
- Ockham Research submits: With the debate continuing to rage around how the government will “fix” our healthcare system, one potential bright spot is in the supplements arena. NBTY, Inc. NTY, formerly known as Nature’s Bounty, reported a 21 percent rise in 4Q net sales as reported on October 13th. ...
- External links 2008-10-17
- Why Is Gilead Buying CV Therapeutics?
- Ockham Research submits: “Another deal believe it or not in the drug industry has just come down. This time Gilead Sciences is buying CV Therapeutics, a $1.4 billion deal. We’ve seen so many acquisitions including Genentech-Roche which we talked about happening in recent days. $1.4 billion for CV Therapeutics...
- External links 2009-03-12
- Pharma: Buying on Merger Spec?
- Ockham Research submits: The merger and acquisition activity in the pharmaceutical sector has made Jim Cramer start to get just a little bit interested in taking a flyer on Isis Pharmaceuticals ISIS. No doubt there are a lot of dollars flying around, but apparently Cramer thinks that the...
- External links 2009-03-16
- Humana Looking Healthier
- Ockham Research submits: “More importantly, guidance for the full year is better than the prior guidance. That’s the important thing for them. Humana is up 8%. Very good news from them. Overall, lower prescription drug claims and medicare premiums were up. That’s good news for them. That stock is...
- External links 2009-04-27
- Cramer Is Not Buying Into the Swine Flu
- Ockham Research submits: “Caller Stephen in New York: I’m calling about QDEL. As you know, they are in the business of influenza diagnosis, with this new swine flu already making headlines, I wonder if you thought there was any mad money to be made here? Jim Cramer: I...
- External links 2009-04-28
- Savient Up Big on Friday
- Ockham Research submits: Savient Pharmaceuticals SVNT is trading about 60% higher in afternoon trading on Friday, and the circumstances surrounding the massive gains a bit perplexing. Savient, a specialty biopharmaceuticals company, has a drug called Krystexxa that is used to treat gout patients. This drug has been...
- External links 2009-06-12
- Medtronic Increasing Dividends and Share Buyback Plan
- Ockham Research submits: On Thursday, Medtronic MDT, which produces and sells medical devices, announced that the board has accepted a plan to raise the quarterly dividend by 9% to more than 20 cents per share. The annual dividend now comes to 82 cents per share and at prices...
- External links 2009-06-18
- Study of Sepracor?s Depression Drug Has Investors Gloomy
- Ockham Research submits: Big percentage move on the down side out of Sepracor. It is down about 16% in the pre-market this morning… There’s Sepracor, $14.85 big drop as a depression drug that failed in a clinical trial. That’s why that stock is getting hammered ahead of the open....
- External links 2009-07-02
- Johnson & Johnson Beats Estimates Yet Again
- Ockham Research submits: “Johnson & Johnson, that’s an important name to the market. Robert: It is indeed. We sort of seeing sort of the best in class coming out first, the valedictorians are stepping out in their fields here with the Johnson & Johnson blue chip and Goldman Sachs,...
- External links 2009-07-14
- McKesson's Prognosis Looking Even Better
- Ockham Research submits: “McKesson out, the Street was looking out for this. Revenues in line and the CEO called the quarter a strong quarter, and the stock opened up strong so that’s great news for McKesson there.” Fox Business Network 7/29/2009 by Ockham Research
- External links 2009-07-29
- Sepracor?s Great Value Recognized by Japan?s Dainippon Sumitomo
- Ockham Research submits: Sepracor SEPR shares surged up to 30% higher in early afternoon trading as news broke from the Nikkei of an approximately $2.71 billion offer from Dainippon Sumitomo. Sepracor’s stock has been hammered over the last few years, and recently there have been some disappointing clinical...
- External links 2009-09-02
- Taking Profits from Swine Flu with Tamiflu
- Ockham Research submits: Flu season is approaching quickly and fresh fears over a possible H1N1 epidemic have taken hold. Hospitals and pharmacies are stocking up on medications to counter such an outbreak, and the most popular drug to treat flu is Tamiflu. Tamiflu was developed by Gilead...
- External links 2009-09-10
- Johnson & Johnson Solid, Yet Sales Fall
- Ockham Research submits: “This is almost a microcosm of everything people are saying; cost cutting and beating on the bottom line is not going to be enough this time and that appears to be what people are thinking about with Johnson & Johnson because the stock just broke under...
- External links 2009-10-13
- Pfizer Wastes No Time Realizing Cost Efficiencies
- Ockham Research submits: The largest deal among drug makers in the last year was completed today as Pfizer PFE officially merged with Wyeth WYE. At the close of trading on Thursday, Wyeth was delisted from the NYSE. Pfizer has wasted no time in announcing some of its...
- External links 2009-10-16
- Boston Scientific?s Return to Profit Is More Bitter than Sweet
- Ockham Research submits: Medical device maker Boston Scientific BSX reported third quarter earnings which showed the company swung back to a profit. Net income came in at $200 million or 12 cents per share after backing out one-time charges, which obviously compares favorably to the period a year...
- External links 2009-10-20
- Gilead Sciences Is in Great Health
- Ockham Research submits: “Check out Gilead. Profit up 36% from a year ago. Well ahead of expectations at 78 cents [non-GAAP] versus a 67 estimate. The revenues grew 31% from a year ago. Product sales strong, royalties strong, but the stock is down. Only thing I can see, that...
- External links 2009-10-21
Additional Resources
- Ford and UAW Working Together
- Ockham Research submits: Perhaps the biggest story of the last week concerning the U.S. automakers has gone by without my fanfare at all. Ford F has come to a labor agreement with the UAW that will allow for it to compete much more effectively with the foreign automakers....
- External links 2009-03-11
- Quality Systems' Management Is Clearly Confident
- Ockham Research submits: It was the summer of 2007 when President Bush proclaimed his goal that every American have an electronic medical record [EMR] within 10 years. At that time only an estimated 25% of all practices had implemented such a system. The benefits of these systems are easy...
- External links 2008-09-23
- << Previous
- page 1 of 1
- Next >>
